Poor
Not Aligned
Patient Risk:
High
Summary
Several claims are unsupported by the provided label content, including route/formulation and substitution guidance. One major claim (IV/injectable use for more serious infections) is contradicted by the provided indication-only labeling scope (acute cystitis; not pyelonephritis/perinephric abscess).
Category Scores
Accurate Statements
Fosfomycin Tromethamine is used for oral use.
Supported by DOSAGE AND ADMINISTRATION (oral dosing/mixing with water) and CLINICAL PHARMACOLOGY (oral absorption/converted after oral administration).
Fosfomycin can be prescribed as 'Fosfomycin tromethamine' for oral use.
Supported by DOSAGE AND ADMINISTRATION (Fosfomycin Tromethamine oral regimen) and CLINICAL PHARMACOLOGY.
Oral fosfomycin (often as fosfomycin tromethamine) is commonly used for urinary tract infections.
Partially supported: label indicates treatment of uncomplicated urinary tract infections/acute cystitis in women due to susceptible strains; label does not support 'commonly' framing.
Unsupported Statements
Fosfomycin is a single antibiotic active ingredient.
Not supported by the provided label sections; label text provided does not establish this phrasing/claim.
Fosfomycin is marketed under different brand names depending on the country.
Not addressed in the provided label sections.
Fosfomycin brand names vary depending on whether it is given as oral fosfomycin or as an IV/injectable form.
Not addressed in the provided label sections.
Oral fosfomycin is used for uncomplicated cystitis in many guidelines and settings.
Label provides indication wording but does not address 'many guidelines and settings.'
IV/injectable fosfomycin is used for more serious infections in hospitals.
Route/indication for IV/injectable use is not supported; the provided label sections specify oral Fosfomycin Tromethamine for acute cystitis and state it is not indicated for pyelonephritis or perinephric abscess.
Clinicians choose antibiotics for hospital-treated infections based on suspected organism(s), severity, and local resistance patterns.
Not addressed in the provided label sections.
Checking the active ingredient spelling and strength and whether it is oral vs injectable is what matters for identifying the formulation.
Not addressed in the provided label sections.
Fosfomycin can be prescribed as 'Fosfomycin' for injectable/IV use.
The provided label sections do not provide injectable/IV product information or administration instructions for such use.
Pharmacists can often substitute based on availability if a prescription is written as fosfomycin active ingredient/formulation.
Not addressed in the provided label sections.
Fosfomycin is an older antibiotic.
Not addressed in the provided label sections.
Fosfomycin is widely available as generics in many markets.
Not addressed in the provided label sections.
Brand exclusivity is usually not the main driver of current availability of fosfomycin.
Not addressed in the provided label sections.
Patent or exclusivity coverage for fosfomycin is formulation- and market-specific.
Not addressed in the provided label sections.
Contradictions
High
AI Statement
IV/injectable fosfomycin is used for more serious infections in hospitals.
Label Reference
INDICATIONS AND USAGE: Fosfomycin Tromethamine is indicated only for uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis, and is not indicated for pyelonephritis or perinephric abscess.
Low
AI Statement
Fosfomycin can be prescribed as 'Fosfomycin' for injectable/IV use.
Label Reference
No injectable/IV product/administration indications or instructions are provided in the provided label sections; available indication language is for acute cystitis in women (oral product context) and excludes other upper-tract conditions.
Important Omissions
No label-supported clarification of the specific indicated population/condition boundaries for acute cystitis vs. pyelonephritis/perinephric abscess when discussing seriousness/routes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Claims suggesting IV/injectable use for more serious infections and that 'Fosfomycin' can be prescribed for IV use are not supported by the provided label scope and could mislead route/indication selection. Dispensing substitution guidance is also not label-supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Unsupported and contradictory claims about IV/injectable use and about prescribing/dispensing substitutions not addressed in the provided label content.
Suggested Improvement
Limit statements to label-supported oral Fosfomycin Tromethamine use for uncomplicated acute cystitis in women due to susceptible strains, and remove/avoid claims about IV/injectable formulations, substitution/dispensing permissions, and country/market availability dynamics not present in the provided label sections.